Rytuksymab: interakcje

The use of RIABNI in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended [see Clinical Studies (14.6) ] . (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Progressive Multifocal Leukoencephalopathy (PML) Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine, primarily in combination with rituximab or obinutuzumab [see Adverse Reactions (6.2) ] . (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)

In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. (etykieta leku Cyklosporyna, Ostrzeżenie w ramce)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (etykieta leku Darunawir, Interakcje z innymi lekami)

The use of RIABNI in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended [see Clinical Studies (14.6) ] . (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (etykieta leku Fludrokortyzon, Ostrzeżenia)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (etykieta leku Flunizolid, Środki ostrożności)

The use of RIABNI in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended [see Clinical Studies (14.6) ] . (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (etykieta leku Itrakonazol, Interakcje z innymi lekami)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (etykieta leku Kaptopryl, Ostrzeżenia)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (etykieta leku Nirmatrelwir + rytonawir, Przeciwwskazania)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Amlodypina, Interakcje z innymi lekami)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Amlodypina + atorwastatyna, Interakcje z innymi lekami)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Amlodypina + olmesartan, Interakcje z innymi lekami)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (etykieta leku Amlodypina + walsartan, Interakcje z innymi lekami)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (etykieta leku Atazanawir, Interakcje z innymi lekami)

Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (etykieta leku Darunawir + kobicystat, Interakcje z innymi lekami)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etykieta leku Denosumab, Ostrzeżenia i środki ostrożności)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (etykieta leku Efawirenz, Interakcje z innymi lekami)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (etykieta leku Efawirenz + lamiwudyna + tenofowir, Interakcje z innymi lekami)

Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (etykieta leku Elwitegrawir + kobicystat + emtrycytabina + tenofowir, Interakcje z innymi lekami)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (etykieta leku Etrawiryna, Interakcje z innymi lekami)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (etykieta leku Fenofibrat, Interakcje z innymi lekami)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (etykieta leku Fosamprenawir, Interakcje z innymi lekami)

Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (etykieta leku Ketokonazol, Interakcje z innymi lekami)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (etykieta leku Kwas fenofibrowy, Interakcje z innymi lekami)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etykieta leku Ledipaswir + sofosbuwir, Ostrzeżenia i środki ostrożności)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (etykieta leku Leflunomid, Ostrzeżenia i środki ostrożności)

Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with KALETRA. (etykieta leku Lopinawir + rytonawir, Interakcje z innymi lekami)

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (etykieta leku Merkaptopuryna, Ostrzeżenia i środki ostrożności)

Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (etykieta leku Mykofenolan, Ostrzeżenia i środki ostrożności)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (etykieta leku Nefazodon, Interakcje z innymi lekami)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (etykieta leku Newirapina, Interakcje z innymi lekami)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Olmesartan + amlodypina + hydrochlorotiazyd, Interakcje z innymi lekami)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etykieta leku Penicylamina, Ostrzeżenia)

Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (etykieta leku Ryfampicyna, Interakcje z innymi lekami)

…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (etykieta leku Ryfapentyna, Interakcje z innymi lekami)

Immunosuppressants: cyclosporine, tacrolimus, sirolimus (rapamycin) ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir. (etykieta leku Rytonawir, Interakcje z innymi lekami)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etykieta leku Sofosbuwir + welpataswir, Ostrzeżenia i środki ostrożności)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Telmisartan + amlodypina, Interakcje z innymi lekami)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etykieta leku Temsyrolimus, Ostrzeżenia i środki ostrożności)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (etykieta leku Tynidazol, Interakcje z innymi lekami)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (etykieta leku Aksytynib, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Atorwastatyna, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

…(14%) 5 (71%) * A baseline platelet count of 50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for… (etykieta leku Bortezomib, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (etykieta leku Ewerolimus, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etykieta leku Ezetymib + symwastatyna, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (etykieta leku Fluwastatyna, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

In the AUGMENT and MAGNIFY trials, Grade 3 or 4 neutropenia was reported in 50% and 33%, respectively, of patients in the REVLIMID/rituximab arm. (etykieta leku Lenalidomid, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Lowastatyna, Ostrzeżenia)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

The effect of rituximab on immune responses was assessed in a randomized, controlled study in patients with RA treated with rituximab and methotrexate (MTX) compared to patients treated with MTX alone. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

For RA, GPA and MPA, and PV patients, methylprednisolone 100 mg intravenously or its equivalent is recommended 30 minutes prior to each infusion. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (etykieta leku Nifedypina, Środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Pitawastatyna, Ostrzeżenia i środki ostrożności)

CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor. (etykieta leku Pozakonazol, Interakcje z innymi lekami)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Prawastatyna, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etykieta leku Propylotiouracyl, Ostrzeżenia)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Rozuwastatyna, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etykieta leku Symwastatyna, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etykieta leku Tiamazol, Ostrzeżenia)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etykieta leku Rytuksymab, Ostrzeżenia i środki ostrożności)

In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. (etykieta leku Rytuksymab, Interakcje z innymi lekami)

In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. (etykieta leku Rytuksymab, Interakcje z innymi lekami)

…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (etykieta leku Klarytromycyna, Interakcje z innymi lekami)